Stock Price, News, Quote and Profile of IO BIOTECH INC(NASDAQ:IOBT) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

IO BIOTECH INC

NASDAQ:IOBT (9/6/2024, 8:21:30 PM)

After market: 0.843 0 (-0.12%)

0.844

-0.05 (-5.71%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-53.63%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap55.60M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The firm develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The firm is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Company Info

IO BIOTECH INC

Ole Maaloes Veh 3

COPENHAGEN

P: 4570702980

Employees: 68

Website: https://www.iobiotech.com/

IOBT News

4 days ago - ChartmillLet's take a look at the stocks that are in motion in today's session.

Let's take a look at the stocks that are in motion in today's session.

4 days ago - ChartmillKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

Which stocks are experiencing notable movement on Tuesday?

4 days ago - ChartmillThese stocks are gapping in today's session

Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.